Labcorp Holdings Inc. · NYSE:LH

Labcorp — Merger or Acquisition (July 2022)

8 slides from Labcorp's merger presentation, Jul 28, 2022

  1. Slide 1: Spin-off of the Clinical Development Business Investor Presentation

    Spin-off of the Clinical Development Business Investor Presentation July 28, 2022

  2. Slide 2: Cautionary Statement Regarding Forward-Looking Statements

    Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements, including but not limited to statements with respect to the proposed spin-off of the Clinical Development business (“CD”), including statements regarding the expectation that the transact

  3. Slide 3: Today's Announcement

    Labcorp Clinical Development • A global market leader providing innovative and • A leading global Contract Research Organization (CRO) advanced laboratory-focused services providing Phase I-IV clinical trial management, market access and technology solutions Today’s • Global capabilities spanning ro

  4. Slide 4: Strategic Rationale for Separation

    Strategic Rationale for Separation Strengthened strategic flexibility and operational focus to pursue specific market opportunities and better meet customer needs Ability to implement focused capital structures and capital allocation strategies to drive innovation and growth A more targeted investme

  5. Slide 5: Labcorp: Strong Growth Platform With a Compelling Value Proposition

    Labcorp Strong Growth Platform With a Compelling Value Proposition $150B+ 650M+ Invest in R&D and innovation to develop and launch diagnostic advancements globally in key areas such as oncology, Alzheimer's, autoimmune and other diseases Global Addressable Market Tests Performed Annually Bring toget

  6. Slide 6: Clinical Development: Leading Global CRO Presents a Focused Investment Opportunity

    Clinical Development Leading Global CRO Presents a Focused Investment Opportunity Focused on growth opportunities across Phase I-IV clinical trials and leadership in key $25B+ 3,900+ therapeutic areas Global Addressable Market Clinical Studies Performed(1) Increased agility with large pharmaceutical

  7. Slide 7: Other Transaction Details

    Other Transaction Details Results in two independent, well-capitalized, publicly-traded companies with the strategic flexibility and operational focus to innovate, grow significantly and enhance shareholder value Intended to qualify as a tax-free transaction for U.S. federal tax purposes to Labcorp

  8. Slide 8: Slide 8

Labcorp Holdings — Merger or Acquisition (July 2022) on 6ix